Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.93 USD | +2.51% | -4.84% | +76.25% |
Mar. 26 | Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating | MT |
Mar. 18 | Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.25% | 1.37B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |
- Stock
- Equities
- Stock Spyre Therapeutics, Inc. - Nasdaq
- News Spyre Therapeutics, Inc.
- Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1